D2C Startup Be Clinical Raises ₹21 Cr in Seed Extension Round
Discover how D2C startup Be Clinical raised ₹21 Cr in its seed extension round in 2026, led by Sauce and V3 Ventures.
LazyFounders
30 SEC SUMMARY
Be Clinical, a D2C skincare startup, raised ₹21 Cr in its seed extension round in 2026, led by Sauce and V3 Ventures. The funding will bolster R&D, expand product lines, and scale manufacturing.
TABLE OF CONTENTS
INTRODUCTION
In 2026, D2C skincare startup Be Clinical announced a significant funding round, raising ₹21 Cr in its seed extension round. The round was led by Sauce, with participation from existing investor V3 Ventures and several angel investors. This funding reflects the growing investor interest in efficacy-led skincare brands as consumers increasingly seek clinically tested products targeting specific concerns.
ABOUT BE CLINICAL
Be Clinical, founded by Hemangi Dhir in 2023, is a Mumbai-based D2C skincare brand that develops clinically tested products containing dermatologically active ingredients to address ageing-related concerns among Indian consumers. The startup undertakes rigorous clinical testing to validate the safety and efficacy of its products before launching them. Be Clinical’s in-house manufacturing setup gives it greater control over product quality and efficacy.
FUNDING DETAILS
The ₹21 Cr seed extension round was led by Sauce, with participation from V3 Ventures and several angel investors, including Mokobara founders Sangeet Agrawal and Navin Parwal, Reckitt SVP and MD for Greater China and North Asia Arjun Purkayastha, and Shaunak Chirayu Amin. The startup plans to use the fresh capital to strengthen its R&D capabilities, expand its skin, body, and haircare portfolio, scale manufacturing capacity, and enter new markets and geographies.
MARKET LANDSCAPE
The beauty and personal care (BPC) market in India was valued at $31.19 Bn in 2025 and is projected to reach $48.72 Bn by 2034, growing at a CAGR of 5.08%, according to IMARC Group. The increasing consumer interest in skincare products containing active ingredients and backed by clinical testing is giving emerging D2C brands another way to differentiate themselves in India’s crowded BPC market.
KEY HIGHLIGHTS
- Be Clinical raised ₹21 Cr in its seed extension round in 2026.
- The round was led by Sauce, with participation from V3 Ventures and several angel investors.
- The startup plans to use the funding to expand its product lines and scale manufacturing.
FAQs
What is Be Clinical's primary sales channel?
Be Clinical’s website is its primary sales channel, but its products are also available on ecommerce marketplaces such as Amazon and Flipkart.
Who are Be Clinical's competitors?
Be Clinical competes with homegrown brands such as Dr Sheth’s, Pilgrim, Innovist, and Mamaearth, as well as global players including Clinique, Neutrogena, and Cetaphil.
What is the projected CAGR of India’s BPC market?
The beauty and personal care market in India is projected to grow at a CAGR of 5.08% from 2025 to 2034.
CONCLUSION
Be Clinical’s recent funding round highlights the growing investor interest in efficacy-led skincare brands. With a strong focus on clinical testing and in-house manufacturing, Be Clinical is well-positioned to capitalize on the expanding BPC market in India.
CALL-TO-ACTION
Stay ahead in India’s startup economy by visiting blogy.in. Unlock special offers and join 10,000+ founders, investors & operators staying ahead in India’s startup economy.
Sources
- inc42.com · 2026-08-22
Be Clinical Bags ₹21 Cr To Double Down On Clinical Skincare
This story is an original summary and analysis written by LazyFounders from the reporting listed above. Facts are attributed to their original publishers; sections marked as analysis are LazyFounders's opinion. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links.
